ReviewAustralian prescriber2019
Influenza: overview on prevention and therapy.
Review in Australian prescriber, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Article
- Vaccine adjuvants: current status, research and development, licensing, and future opportunities.Journal of materials chemistry. B · 2024Review
- Late diagnosis of respiratory syncytial virus and influenza co-infection during coronavirus disease 2019 pandemic: a case report.Journal of medical case reports · 2023Article
- A Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2.Frontiers in microbiology · 2022Review
- Review
- Managing the overlap of asthma and chronic obstructive pulmonary disease.Australian prescriber · 2020Review
- Flu vaccination when travelling between countries.Australian prescriber · 2019Article
- Peramivir for influenza.Australian prescriber · 2019Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
QUADRIVALENT INFLUENZA VACCINATION IS RECOMMENDED ANNUALLY FOR ADULTS AND CHILDREN AGED SIX MONTHS TO 64 YEARS: HIGH-DOSE OR ADJUVANTED TRIVALENT VACCINES ARE RECOMMENDED ANNUALLY FOR PEOPLE 65 YEARS AND OVER: IF STARTED EARLY ENOUGH NEURAMINIDASE INHIBITORS REDUCE SYMPTOM DURATION BY APPROXIMATELY ONE DAY TREATMENT SHOULD BE CONSIDERED IN PATIENTS WITH SEVERE DISEASE REQUIRING HOSPITALISATION OR WHO ARE AT RISK OF COMPLICATIONS: CHEMOPROPHYLAXIS IS NOT A SUBSTITUTE FOR VACCINATION BUT CAN BE CONSIDERED IN HIGH-RISK INDIVIDUALS WITH AN INADEQUATE OR INEFFECTIVE VACCINATION STATUS:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.